 |
Top 10 Atherosclerosis treatment startups in USA
Oct 12, 2024 | By Jason Kwon | 16 |
1
Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
2
Funding: $733.1M
Humacyte develops novel human tissue-based investigational products for potential applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
Humacyte develops novel human tissue-based investigational products for potential applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
3
Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
4
Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
5
Funding: $333.1M
Avinger designs, develops and manufactures precision medical device technology to fight Peripheral Artery Disease and help patients keep their legs.
Avinger designs, develops and manufactures precision medical device technology to fight Peripheral Artery Disease and help patients keep their legs.
6
Funding: $250M
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
7
Funding: $145.4M
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease.
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease.
8
Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
9
Funding: $129.7M
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
10
Funding: $98M
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
